• 07. 01, 14 NovioGendix signs co-­development deal with DDL Diagnostic Laboratory for development of novel IVD prostate cancer test
  • Nijmegen -­ NovioGendix, the molecular biomarker company developing tests for GU cancer diagnosis, prognosis and .... Read more..

  • 04. 12, 13 PCA3: Zorg op Maat
  • PCA3 in Zorg op maat bijlage van De Telegraaf: .... Read more..


    NovioGendix, based in Nijmegen (The Netherlands), is a molecular diagnostic research and service company providing an expert-based, integrated approach in developing advanced and clinically useful molecular diagnostic assays for the uro-oncological practice.


    NovioGendix Research focuses on biomarker-based diagnostic product development for uro-oncological diseases. In its R&D program the company conducts multiple retrospective and prospective clinical studies in prostate-, bladder- and kidney cancer.


    NovioGendix Servicelab provides ProgensaŽ PCA3 testing services according to the highest professional standards, with a quick turn-around time of only 7 days*.